Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
Phase 3
Completed
- Conditions
- Arterial HypertensionAlbuminuria
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 43
- Registration Number
- NCT02376075
- Locations
- 🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Rhineland-Palatinate, Germany
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Phase 4
- Conditions
- Diabetes Mellitus Type II
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 44
- Registration Number
- NCT01565096
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Germany
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
Phase 4
- Conditions
- Insulin-requiring Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2011-12-29
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT01500850
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Rheinland-Pfalz, Germany
Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study
Phase 4
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT01417897
- Locations
- 🇩🇪
ife GmbH, Clinic, Mainz, Rhineland-Palatinate, Germany
Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 44
- Registration Number
- NCT01208012
- Locations
- 🇩🇪
IKFE Institute for Clinical Research and Development, Mainz, Germany
Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2010-09-22
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 120
- Registration Number
- NCT01206647
- Locations
- 🇩🇪
Zentrum für klinische Studien Dresden, GWT-TUD GmbH, Dresden, Germany
🇩🇪Diabetes Zentrum Neuwied, Neuwied, Germany
🇩🇪Diabetologische Schwerpunktpraxis Dr. Lorra / Dr. Bonnermann, Bochum, Germany
Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2010-09-22
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 106
- Registration Number
- NCT01206712
- Locations
- 🇩🇪
IKFE Institute for Clinical Research and Development, Mainz, Germany
Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin
Phase 4
Completed
- Conditions
- Type 2 Diabetic PatientsInsufficient Metabolic ControlOAD Treatment
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT00941148
- Locations
- 🇩🇪
ikfe GmbH, Clinic Department, Mainz, RLP, Germany
© Copyright 2025. All Rights Reserved by MedPath